Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE)

NCT03812796 is registered in ClinicalTrials.gov with Royal Marsden NHS Foundation Trust as lead sponsor.

NCT NCT03812796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03812796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE)
Lead sponsor
Royal Marsden NHS Foundation Trust
Phase
Phase 2
Overall status
Unknown status
Start date
January 11, 2019
Completion date
November 30, 2021
Enrollment
75 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, gi cancer